drugset / Trial / NCT04956484
Belimumab In Early Systemic Lupus Erythematosus
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy of belimumab in early SLE patients (disease duration less than 6 months).
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-04-08
- Completion
- 2022-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belimumab | Monoclonal antibody | 10 mg/kg | — |
| Background | AZA | Unknown | — | — |
| Background | CTX | Unknown | — | — |
| Background | CsA | Unknown | — | — |
| Background | HCQ | Unknown | — | — |
| Background | LEF | Unknown | — | — |
| Background | MMF | Unknown | — | — |
| Background | MTX | Unknown | — | — |
| Background | SASP | Unknown | — | — |
| Background | Tacrolimus | Small molecule | — | — |